CIGNA announced a positive coverage policy for minimally invasive sacroiliac joint fusion exclusive for FDA-cleared implants that are placed across the SI joint, such as SI-BONE's iFuse Implant System.
CartiHeal announced that per the results of an interim analysis of the IDE study of Agili-C™ in the treatment of cartilage lesions, trial enrollment will stop at 250 subjects.